Institute of Health and Wellbeing, University of Glasgow, G12 8RZ, Glasgow, UK.
British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Science, University of Glasgow, G12 8TA, Glasgow, UK.
Age Ageing. 2020 Feb 27;49(2):300-304. doi: 10.1093/ageing/afz126.
recently, the European Working Group on Sarcopenia in Older People (EWGSOP) established a new operational definition and cut-off points for sarcopenia. The aim of this study was, therefore, to compare the prevalence of sarcopenia and its associations with different health outcomes using the old (EWGSOP1) and new (EWGSOP2) definitions of sarcopenia in the UK Biobank cohort.
sarcopenia was defined as low grip strength plus low muscle mass. Using both EWGSOP cut-off points, we created specific sarcopenia variables. Prevalence of sarcopenia derived using both EWGSOP definitions was calculated and compared as well as prospective health outcomes including all-cause mortality as well as incidence and mortality from cardiovascular disease (CVD), respiratory disease and chronic obstructive pulmonary disease (COPD).
the prevalence of sarcopenia based on the EWGSOP1 and EWGSOP2 classifications were 8.14 and 0.36%, respectively. Sarcopenia defined by EWGSOP1 was associated with a higher risk of respiratory disease and COPD as well as mortality from all-cause, CVD and respiratory diseases. However, only respiratory incidence remained associated with sarcopenia when EWGSOP2 was used (HR: 1.32 [95% CI: 1.05-1.66]). Moreover, although individuals classified as sarcopenic using both classifications had the highest risk of all-cause mortality and respiratory disease, those with sarcopenia based on EWGSOP1 only experienced a more extensive range of poorer health outcomes.
in comparison with EWGSOP1, the new classification (EWGSOP2) produced a lower estimate of sarcopenia prevalence and fewer associations with adverse health outcomes. Although these associations were higher, many become non-significant.
最近，欧洲老年人肌肉减少症工作组（EWGSOP）建立了新的操作性定义和肌少症切点。因此，本研究旨在比较使用 UK Biobank 队列中旧（EWGSOP1）和新（EWGSOP2）肌少症定义评估肌少症的患病率及其与不同健康结局的关系。
肌少症定义为握力低伴肌肉量低。使用两种 EWGSOP 切点，我们创建了特定的肌少症变量。使用两种 EWGSOP 定义计算并比较肌少症的患病率，并前瞻性评估全因死亡率以及心血管疾病（CVD）、呼吸疾病和慢性阻塞性肺疾病（COPD）的发病率和死亡率。
基于 EWGSOP1 和 EWGSOP2 分类的肌少症患病率分别为 8.14%和 0.36%。EWGSOP1 定义的肌少症与呼吸疾病和 COPD 以及全因、CVD 和呼吸疾病死亡率的风险增加相关。然而，当使用 EWGSOP2 时，只有呼吸发病率与肌少症相关（HR：1.32[95%CI：1.05-1.66]）。此外，尽管使用两种分类均被归类为肌少症的个体具有最高的全因死亡率和呼吸疾病风险，但仅基于 EWGSOP1 的肌少症患者经历了更广泛的一系列较差的健康结局。
与 EWGSOP1 相比，新分类（EWGSOP2）产生了较低的肌少症患病率估计值，与不良健康结局的相关性也较少。虽然这些相关性更高，但许多相关性变得不显著。
